Brain Cancer

Phase II Trial of Bevacizumab/Trebananib Combo Fails to Demonstrate Improvements
March 17, 2020
ByHannah Slater

Though the combination of bevacizumab and trebananib was found to be well tolerated, it did not significantly improve survival outcomes for patients with recurrent glioblastoma over bevacizumab alone.

Racial/Ethnic Disparities in Pediatric Patients with Brain Cancer
March 16, 2020
ByHannah Slater

A population-based analysis found that racial and ethnic disparities in childhood central nervous system tumor survival seem to have their roots at least partially in post-diagnosis factors, possibly due to the lack of access to high quality care, leading to poorer overall outcomes.

FDA Accepts BLA for Proposed Biosimilar to Bevacizumab, MYL-1402O
March 09, 2020
ByHannah Slater

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.